Steve Connor
Corporate Officer/Principal bij AM-Pharma BV
Actieve functies van Steve Connor
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Corporate Officer/Principal | 17-04-2009 | - |
Loopbaan van Steve Connor
Eerdere bekende functies van Steve Connor
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
pSiMedica Ltd.
pSiMedica Ltd. Miscellaneous Commercial ServicesCommercial Services Part of EyePoint Pharmaceuticals, Inc., pSiMedica Ltd. is a British company that researches and develops nanostructured porous silicon. The company is based in Malvern, UK. The company was founded by Sam di Giacomo. The CEO is Roger Aston. pSiMedica was acquired by EyePoint Pharmaceuticals, Inc. on August 05, 2004 for $40.97 million. | Corporate Officer/Principal | 01-01-2001 | - |
Murex Corp. | Corporate Officer/Principal | - | - |
Chiroscience Group Plc | Corporate Officer/Principal | - | - |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - | - |
Cantab Pharmaceuticals Plc
Cantab Pharmaceuticals Plc MiscellaneousMiscellaneous Cantab Pharmaceuticals plc, based in Cambridge, England, was established in 1989 to exploit advances in immunology. Since that time, Cantab has become a leader in the areas of immunotherapy and gene delivery and has developed a broad portfolio of novel products for the treatment and prevention of many chronic infectious diseases, cancer and substance addiction. | Corporate Officer/Principal | - | - |
Statistieken
Internationaal
Verenigd Koninkrijk | 4 |
Nederland | 2 |
Zwitserland | 2 |
Operationeel
Corporate Officer/Principal | 6 |
Sectoraal
Health Technology | 3 |
Commercial Services | 3 |
Miscellaneous | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Cantab Pharmaceuticals Plc
Cantab Pharmaceuticals Plc MiscellaneousMiscellaneous Cantab Pharmaceuticals plc, based in Cambridge, England, was established in 1989 to exploit advances in immunology. Since that time, Cantab has become a leader in the areas of immunotherapy and gene delivery and has developed a broad portfolio of novel products for the treatment and prevention of many chronic infectious diseases, cancer and substance addiction. | Miscellaneous |
Chiroscience Group Plc | Commercial Services |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Murex Corp. | |
pSiMedica Ltd.
pSiMedica Ltd. Miscellaneous Commercial ServicesCommercial Services Part of EyePoint Pharmaceuticals, Inc., pSiMedica Ltd. is a British company that researches and develops nanostructured porous silicon. The company is based in Malvern, UK. The company was founded by Sam di Giacomo. The CEO is Roger Aston. pSiMedica was acquired by EyePoint Pharmaceuticals, Inc. on August 05, 2004 for $40.97 million. | Commercial Services |
- Beurs
- Insiders
- Steve Connor
- Ervaring